Trending NewsTrending NewsNASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $7.62 -0.36 (-4.51%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$7.62 0.00 (0.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Enanta Pharmaceuticals Stock (NASDAQ:ENTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enanta Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.56▼$8.0650-Day Range$7.62▼$13.2052-Week Range$7.56▼$17.15Volume457,635 shsAverage Volume340,292 shsMarket Capitalization$222.20 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingModerate Buy Company Overview Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies. The company continues to advance a pipeline of investigational medicines, including programs targeting RSV and other viral diseases, as well as inflammatory disorders. These candidates remain subject to clinical development and regulatory review.AI Generated. May Contain Errors. Read More Enanta Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreENTA MarketRank™: 2.320527201345 of 5 starsEnanta Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 521st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEnanta Pharmaceuticals has a consensus price target of $19.00, representing about 149.3% upside from its current price of $7.62.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($2.24) to ($2.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.20% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 7.63.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 18.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.29 News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.48% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTA Stock News HeadlinesJPMorgan Chase & Co. Issues Pessimistic Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock PriceNovember 22 at 2:18 AM | americanbankingnews.comEquities Analysts Set Expectations for ENTA Q1 EarningsNovember 21 at 2:12 AM | americanbankingnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 22 at 1:00 AM | Porter & Company (Ad)Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by Wall Street ZenNovember 21 at 1:12 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Moleculin Biotech (MBRX)November 18, 2026 | theglobeandmail.comEnanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2026November 17, 2026 | marketscreener.comMEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026November 16, 2026 | marketscreener.comMEnanta Pharmaceuticals Fiscal Q4 Loss Narrows, Revenue FallsNovember 16, 2026 | marketscreener.comMSee More Headlines ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $15.77 at the beginning of the year. Since then, ENTA shares have decreased by 51.7% and is now trading at $7.62. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its earnings results on Monday, November, 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.09. The biotechnology company earned $12.87 million during the quarter, compared to the consensus estimate of $14.62 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 64.32% and a negative net margin of 108.33%. When did Enanta Pharmaceuticals IPO? Enanta Pharmaceuticals (ENTA) raised $60 million in an initial public offering on Thursday, March 21st 2013. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' top institutional investors include State Street Corp (1.97%), Goldman Sachs Group Inc. (1.47%), Marshall Wace LLP (0.25%) and Jump Financial LLC (0.20%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus, Kathleen S Capps and Terry Vance. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Gilead Sciences (GILD), Tesla (TSLA), Micron Technology (MU), Bristol Myers Squibb (BMY), GE Aerospace (GE), NVIDIA (NVDA) and Palo Alto Networks (PANW). Company Calendar Last Earnings11/16/2026Today11/22/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Next Earnings (Estimated)2/08/2027Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, ENTA's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENTA CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees120Year Founded1995Price Target and Rating Average Price Target for Enanta Pharmaceuticals$19.00 High Price Target$20.00 Low Price Target$17.00 Potential Upside/Downside+149.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.89 million Net Margins-108.33% Pretax Margin-108.26% Return on Equity-64.32% Return on Assets-22.44% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.76 Sales & Book Value Annual Sales$63 million Price / Sales3.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.77Miscellaneous Outstanding Shares29,160,000Free Float25,812,000Market Cap$222.20 million OptionableOptionable Beta0.75 Social Links 7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and GoogleCould the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.Get This Free Report This page (NASDAQ:ENTA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredRetirement balance looks fine, so why do you feel behind?Does your retirement balance look fine while you still feel like you're falling behind? On Wednesday, December...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.